652 related articles for article (PubMed ID: 27460179)
21. Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group.
Wada N; Zaki MA; Kohara M; Ogawa H; Sugiyama H; Nomura S; Matsumura I; Hino M; Kanakura Y; Inagaki H; Morii E; Aozasa K
Histopathology; 2012 May; 60(6):924-32. PubMed ID: 22321065
[TBL] [Abstract][Full Text] [Related]
22. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
Laszlo D; Pruneri G; Andreola G; Radice D; Calabrese L; Rafaniello PR; Nassi L; Sammassimo S; Alietti A; Agazzi A; Vanazzi A; Martinelli G
Int J Surg Pathol; 2011 Aug; 19(4):417-24. PubMed ID: 19793830
[TBL] [Abstract][Full Text] [Related]
23. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).
Jackson AE; Mian M; Kalpadakis C; Pangalis GA; Stathis A; Porro E; Conconi A; Cortelazzo S; Gaidano G; Lopez Guillermo A; Johnson PW; Martelli M; Martinelli G; Thieblemont C; McPhail ED; Copie-Bergman C; Pileri SA; Jack A; Campo E; Mazzucchelli L; Ristow K; Habermann TM; Cavalli F; Nowakowski GS; Zucca E
Oncologist; 2015 Oct; 20(10):1149-53. PubMed ID: 26268740
[TBL] [Abstract][Full Text] [Related]
24. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
Wang C; Li W; Liu C; He H; Bai O
Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
[TBL] [Abstract][Full Text] [Related]
25. Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions.
Yoon JS; Ma KT; Kim SJ; Kook K; Lee SY
Ophthalmic Plast Reconstr Surg; 2007; 23(2):94-9. PubMed ID: 17413620
[TBL] [Abstract][Full Text] [Related]
26. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
[TBL] [Abstract][Full Text] [Related]
27. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab.
Benesova K; Forsterova K; Votavova H; Campr V; Stritesky J; Velenska Z; Prochazka B; Pytlik R; Trneny M
Neoplasma; 2013; 60(1):68-73. PubMed ID: 23067219
[TBL] [Abstract][Full Text] [Related]
28. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
29. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
30. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
[TBL] [Abstract][Full Text] [Related]
31. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Br J Haematol; 2016 Oct; 175(2):275-280. PubMed ID: 27443247
[TBL] [Abstract][Full Text] [Related]
32. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
33. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
Ye ZY; Cao YB; Lin TY; Lin HL
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
[TBL] [Abstract][Full Text] [Related]
34. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
36. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
37. Conjunctival Lymphoma--An International Multicenter Retrospective Study.
Kirkegaard MM; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Toft PB; Vemuganti GK; Thuro BA; Curtin J; Heegaard S
JAMA Ophthalmol; 2016 Apr; 134(4):406-14. PubMed ID: 26891973
[TBL] [Abstract][Full Text] [Related]
38. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
[TBL] [Abstract][Full Text] [Related]
39. [Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type].
Li BZ; Zhou XY; Ye HT; Yang WT; Fan YZ; Lu HF; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2007 Dec; 36(12):819-24. PubMed ID: 18346354
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the clinical characteristics and prognostic factors of gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma.
Xu X; Wang Z; Yu Y; Wang Y; Zhang L; Sun B; Da W; Zhang Y
J Gastroenterol Hepatol; 2014 Sep; 29(9):1678-84. PubMed ID: 24730769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]